Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.

Gastroenterology - 1 Feb 2011

Shimakami Tetsuro, Welsch Christoph, Yamane Daisuke, McGivern David R, Yi Minkyung, Zeuzem Stefan, Lemon Stanley M

Abstract excerpt

BACKGROUND & AIMS: Several small molecule inhibitors of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease have advanced successfully to clinical trials. However, the selection of drug-resistant mutants is a significant issue with protease inhibitors (PIs). A variety of amino acid substitutions in the protease domain of NS3 can lead to PI resistance. Many of these significantly impair the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Fitness

Share to Hepacivirus

Share to Protease Inhibitors

Share to Replicon

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 21056040
DOI: 10.1053/j.gastro.2010.10.056
PMCID: PMC3155954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.PMID 21056040Read ↗

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: <i>In Vitro</i> Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life CycleSemantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.Semantic proximity Read ↗

Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations.Semantic proximity Read ↗

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.Semantic proximity Read ↗

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.Semantic proximity Read ↗

Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Semantic proximity Read ↗

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.Semantic proximity Read ↗

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.Semantic proximity Read ↗

In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.Semantic proximity Read ↗

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Semantic proximity Read ↗

<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.